12/2
08:47 am
npce
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
Low
Report
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
12/2
08:01 am
npce
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
Medium
Report
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
11/24
08:00 am
npce
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
Medium
Report
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
11/9
12:53 am
npce
NeuroPace (NPCE) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
NeuroPace (NPCE) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/8
09:46 am
npce
NeuroPace, Inc. (NASDAQ:NPCE) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
NeuroPace, Inc. (NASDAQ:NPCE) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
11/5
09:40 pm
npce
NeuroPace (NPCE): High Growth Forecast and Path to Profitability Reinforce Bullish Narratives [Yahoo! Finance]
Low
Report
NeuroPace (NPCE): High Growth Forecast and Path to Profitability Reinforce Bullish Narratives [Yahoo! Finance]
11/5
03:01 pm
npce
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $18.00. They now have an "overweight" rating on the stock.
11/5
10:49 am
npce
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at Wells Fargo & Company from $15.00 to $16.00. They now have an "overweight" rating on the stock.
Medium
Report
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at Wells Fargo & Company from $15.00 to $16.00. They now have an "overweight" rating on the stock.
11/5
07:19 am
npce
NeuroPace (NASDAQ:NPCE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
High
Report
NeuroPace (NASDAQ:NPCE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/5
07:19 am
npce
NeuroPace (NASDAQ:NPCE) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
High
Report
NeuroPace (NASDAQ:NPCE) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/4
11:08 pm
npce
NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down [Seeking Alpha]
High
Report
NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down [Seeking Alpha]
11/4
04:05 pm
npce
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
High
Report
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
10/22
08:00 am
npce
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
10/8
12:30 pm
npce
NeuroPace (NASDAQ:NPCE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
NeuroPace (NASDAQ:NPCE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.